First-line therapy of chronic myeloid leukemia – focus on dasatinib
Philip C AmreinHematology-Oncology, Massachusetts General Hospital, Boston, USAAbstract: Dasatinib is a broad spectrum, ATP-competitive, tyrosine kinase inhibitor with low nM activity against Bcr-Abl, Src, and other tyrosine kinases. This activity has allowed dasatinib to emerge as one of the most e...
Saved in:
| Main Author: | |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Dove Medical Press
2012
|
| Subjects: | |
| Online Access: | https://doaj.org/article/8e4489f7dd2b4887984e6baf19837865 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|